SCHEMBL20064048

SCHEMBL20064048

CNC(=O)c1ccc(C)c(C(C)(C)C)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC2 Q92769 1/20 0.46
EPHX2 P34913 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
PLAU P00749 1/20 0.44
HPGD P15428 2/20 0.43
HTT P42858 2/20 0.43
TSHR P16473 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MMP13 P45452 1/20 0.42
HDAC1 Q13547 1/20 0.42
PLK1 P53350 4/20 0.42
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
HSD17B10 Q99714 1/20 0.41
THRB P10828 1/20 0.41
MAPK14 Q16539 3/20 0.40
MAPK11 Q15759 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15158511 0.86 PLAU (0.47) HDAC6HDAC8HDAC2EPHX2NR1H4
SCHEMBL21968466 0.85 HDAC8 (0.52) HDAC6HDAC8HDAC2EPHX2NR1H4
SCHEMBL13870617 0.84 ADCY8 (0.50) HDAC6HDAC8HDAC2PLAUHPGD
SCHEMBL20073523 0.83 PLK1 (0.45) HDAC6HDAC8HDAC2EPHX2NR1H4
SCHEMBL12068769 0.81 PTGS1 (0.49) EPHX2NR1H4HPGDMAPK14
SCHEMBL24252063 0.81 KMT2A (0.44) HDAC6HDAC8HDAC2EPHX2NR1H4
SCHEMBL12252223 0.81 TAS1R3 (0.46) HDAC6HDAC8HDAC2EPHX2NR1H4
SCHEMBL20206539 0.80 CNR2 (0.52) EPHX2NR1H4HPGDHTTMAPT
SCHEMBL9139322 0.79 RARB (0.49) EPHX2TSHRSMN1; SMN2HSD17B10GAA
SCHEMBL20073521 0.79 HPGD (0.53) HPGDHTTSMN1; SMN2MMP13KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10364247-B2 Preparation and use of novel protein kinase inhibitors RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE (CN) 2019-07-30 US disclosed
US-20180105528-A1 PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS BRANDEIS UNIVERSITY 2018-04-19 US disclosed
US-20180105528-A1 PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS BRANDEIS UNIVERSITY 2018-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10364247-B2 Preparation and use of novel protein kinase inhibitors MAP3K20, MAP3K19, MAP3K5 HDAC6 990/4885HDAC8 1216/4885HDAC2 2030/4885
US-20180105528-A1 PREPARATION AND USE OF NOVEL PROTEIN KINASE INHIBITORS MAP3K20, MAP3K19, MAP3K5 HDAC6 990/4885HDAC8 1216/4885HDAC2 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.